• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Mesoblast Limited (Amendment)

    9/6/23 10:38:48 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MESO alert in real time by email
    SC 13G/A 1 d58712dsc13ga.htm MESOBLAST LIMITED Mesoblast Limited

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 10)*

     

     

    Mesoblast Limited

    (Name of Issuer)

    Common Stock/American Depositary Receipt

    (Title of Class of Securities)

    Q6005U107/590717104

    (CUSIP Number)

    31st August 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.: Q6005U107/590717104

     

      1.   

    Names of Reporting Persons:

     

    M&G Investment Management Limited

    No I.R.S. Identification Number

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☐

     

      3.  

    SEC Use Only

     

      4.  

    Citizenship or Place of Organization:

     

    United Kingdom, England

    Number of Shares Beneficially Owned By Each Reporting Person With:    5.    

    Sole Voting Power:

     

    26,071,085

       6.   

    Shared Voting Power:

     

    0

       7.   

    Sole Dispositive Power:

     

    26,071,085

       8.   

    Shared Dispositive Power:

     

    0

      9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person:

     

    26,071,085

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ☐

     

    11.  

    Percent of Class Represented by Amount in Row (9):

     

    3.20%

    12.  

    Type of Reporting Person (See Instructions):

     

    IA

     

    2


    CUSIP No.: Q6005U107/590717104

     

      1.   

    Names of Reporting Persons:

     

    M&G Investment Funds (3)

    No I.R.S Identification Number

      2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☐

     

      3.  

    SEC Use Only

     

      4.  

    Citizenship or Place of Organization:

     

    United Kingdom, England

    Number of Shares Beneficially Owned By Each Reporting Person With:    5.    

    Sole Voting Power:

     

    0

       6.   

    Shared Voting Power:

     

    0

       7.   

    Sole Dispositive Power:

     

    0

       8.   

    Shared Dispositive Power:

     

    0

      9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person:

     

    26,071,085

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ☐

     

    11.  

    Percent of Class Represented by Amount in Row (9):

     

    3.20%

    12.  

    Type of Reporting Person (See Instructions):

     

    IV

     

    3


    Item 1.

     

    (a)

    Name of Issuer: Mesoblast Limited

     

    (b)

    Address of Issuer’s Principal Executive Offices: Level 38, 55 Collins Street, Melbourne 3000, Australia

    Item 2.

     

    (a)

    Name of Person Filing:

    M&G Investment Management Limited

    M&G Investment Funds (3)

     

    (b)

    Address of Principal Business Office or, if none, Residence: 10 Fenchurch Avenue, London, EC3M 5AG

     

    (c)

    Citizenship: United Kingdom, England

     

    (d)

    Title of Class of Securities: Common Stock Class / American Depositary Receipt

     

    (e)

    CUSIP Number: Q6005U107/590717104

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

    (b) ☐

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c) ☐

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

    (d) ☐

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

    (e) ☒

    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

    (f) ☐

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

    (g) ☐

    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

    (h) ☐

    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i) ☐

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j) ☐

    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).

    (k) ☐

    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    (e)

    MAGIM is an investment adviser in accordance with s.240.13d-1(b)(1)(ii)(E)

    All the securities covered by this report are legally owned by MAGIMs Investment advisory clients, and none are directly owned by MAGIM. M&G Investment Funds (3) is an open-ended investment company with variable capital, incorporated in England and Wales and authorized by the Financial Conduct Authority. It is not registered with the Securities Exchange Commission under the Investment Company Act of 1940

     

    4


    Item 4. Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    M&G Investment Management Limited

    (a) Amount beneficially owned: 26,071,085

    (b) Percent of class: 3.20%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 26,071,085

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 26,071,085

    (iv) Shared power to dispose or to direct the disposition of: 0

    M&G Investment Funds (3)

    (a) Amount beneficially owned: 26,071,085

    (b) Percent of class: 3.20%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

    Item 5. Ownership of Five Percent or Less of a Class

    Not Applicable

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    5


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:     5th September 2023

     

    M&G Investment Management Limited
    By:  

    LOGO

     

    Name: Owen Smith
    Title: Position Reporting Manager
    M&G Investment Funds (3)
    By:  

    LOGO

     

    Name: Owen Smith
    Title: Position Reporting Manager

     

    6


    EXHIBIT INDEX

     

    Ex.         Page No.  
    A.    Joint Filing Agreement      8  

     

    7


    EXHIBIT A

    JOINT FILING AGREEMENT

    The undersigned hereby agree that the statement on Schedule 13G with respect to Common Stock of Mesoblast Limited dated as of 31 August 2023 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

    Date: 5th September 2023

     

    M&G Investment Management Limited
    By:  

    LOGO

     

    Name: Owen Smith
    Title: Regulatory Reporting Team Leader
    M&G Investment Funds (3)
    By:  

    LOGO

     

    Name: Owen Smith
    Title: Regulatory Reporting Team Leader

     

    8

    Get the next $MESO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MESO

    DatePrice TargetRatingAnalyst
    12/23/2024Buy → Hold
    Jefferies
    9/24/2024$12.00Hold → Buy
    Maxim Group
    8/29/2024Hold → Buy
    Jefferies
    7/23/2024$4.00 → $11.00Neutral → Overweight
    Piper Sandler
    8/31/2023Hold → Buy
    Jefferies
    8/7/2023Buy → Hold
    Maxim Group
    8/4/2023$7.00 → $2.00Overweight → Neutral
    Piper Sandler
    8/4/2023Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $MESO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

      NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. This period of statutory exclusivity means that the FDA will not approve another mesenchymal stromal or stem cell (MSC) products for this indication during the 7-year period from the approval of Ryoncil®. Separately, Mesoblast has biologic exclusivity prev

      5/14/25 10:57:06 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

      NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. "We were very pleased to have made Ryoncil® (remestemcel-L) commercially available to treat children with acute GVHD within one quarter of receiving FDA approval as the first mesenchymal stromal cell (MSC) therapy approved in the US for any indication," said Dr. Silviu Itescu, CEO of Mesoblast. "With our strong cash position we are well placed to expand Ryoncil® indications to other serious and life-threatening pediatric inflammatory di

      4/29/25 8:53:27 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited. Ms. Cobley is currently a director of Commonwealth Bank of Australia, is a member of Chief Executive Women, a member of the Macquarie

      4/28/25 7:44:18 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    Leadership Updates

    Live Leadership Updates

    See more
    • Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

      NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. "We were very pleased to have made Ryoncil® (remestemcel-L) commercially available to treat children with acute GVHD within one quarter of receiving FDA approval as the first mesenchymal stromal cell (MSC) therapy approved in the US for any indication," said Dr. Silviu Itescu, CEO of Mesoblast. "With our strong cash position we are well placed to expand Ryoncil® indications to other serious and life-threatening pediatric inflammatory di

      4/29/25 8:53:27 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited. Ms. Cobley is currently a director of Commonwealth Bank of Australia, is a member of Chief Executive Women, a member of the Macquarie

      4/28/25 7:44:18 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dr. Gregory George MD PhD Joins Mesoblast Board

      NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast's largest shareholder, to its Board of Directors. Dr. George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George brings to the Board his background as a medical scientist with unique operational experience having built a start-up company in the medical field and turning it into a highly-efficient multi-billion-dollar commercial organization. Mesoblast Founder and Chief

      2/23/25 6:33:52 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mesoblast downgraded by Jefferies

      Jefferies downgraded Mesoblast from Buy to Hold

      12/23/24 7:24:07 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast upgraded by Maxim Group with a new price target

      Maxim Group upgraded Mesoblast from Hold to Buy and set a new price target of $12.00

      9/24/24 8:11:34 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast upgraded by Jefferies

      Jefferies upgraded Mesoblast from Hold to Buy

      8/29/24 7:56:03 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    SEC Filings

    See more
    • SEC Form 6-K filed by Mesoblast Limited

      6-K - MESOBLAST LTD (0001345099) (Filer)

      5/14/25 8:46:57 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Mesoblast Limited

      6-K - MESOBLAST LTD (0001345099) (Filer)

      4/29/25 9:39:45 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Mesoblast Limited

      6-K - MESOBLAST LTD (0001345099) (Filer)

      4/29/25 7:13:53 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    Financials

    Live finance-specific insights

    See more
    • Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

      NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended June 30, 2024. Mesoblast Chief Executive Silviu Itescu said: "During the past year we have built significant momentum in our interactions with the United States Food and Drug Administration (FDA) across each of our Phase 3 products. I am very pleased that our Biologics License Application (BLA) resubmission for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD)

      8/28/24 7:27:43 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

      NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023. Mesoblast Chief Executive Silviu Itescu said: "We were very busy operationally during the last quarter and continued to have positive engagement with the United States Food and Drug Administration (FDA) across our lead programs. We have strengthened our balance sheet while maintaining overall spending constraint in line with our corporate objectives. For our product Ryoncil® (remestemcel-L) for life-threatening steroid-ref

      2/28/24 5:57:09 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023

      NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview of upcoming milestones. Mesoblast Chief Executive Silviu Itescu said: "We had anticipated that remestemcel-L would have been approved by the United States Food and Drug Administration (FDA) for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD), a condition with a high mortality where there are no approved therapies for children under 12 years old. During the six-month B

      8/30/23 7:07:02 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MESO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

      SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

      12/16/24 12:08:07 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

      SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

      10/9/24 3:42:14 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

      SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

      7/11/24 7:38:31 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care